查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1856610

阿片类药物引起的便秘市场（依产品类型划分：口服、直肠给药）－2025-2032年全球预测

Opioid Induced Constipation Market by Product Type, Oral, Rectal - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，阿片类药物引起的便秘市场规模将成长 1.1994 亿美元，复合年增长率为 6.94%。

关键市场统计数据
基准年 2024 7010万美元
预计年份：2025年 7503万美元
预测年份 2032 1.1994亿美元
复合年增长率 (%) 6.94%

将鸦片类药物引起的便秘视为一项亟待解决的临床品质和病患体验问题，需要整合式照护路径和产品创新。

阿片类药物引起的便秘 (OIC) 是阿片类药物治疗的一种持续且复杂的併发症，会影响患者的依从性、生活品质和临床疗效。由于阿片类药物处方仍然是急性和慢性疼痛管理的重要组成部分，OIC 已成为可预测的副作用，需要积极评估和全面管理策略。临床医生、付款者和产品开发人员必须兼顾有效缓解疼痛和保护胃肠道功能的双重需求，从而推动新的临床路径和支持性护理创新。

现代医疗实践越来越强调分阶段介入方法，首先是早期识别风险，然后制定个人化的预防方案、生活方式指导和选择合适的泻药，最后根据需要升级到标靶药物。同时，支付方和医疗系统也在重新评估药品目录、报销政策和价值框架，以纳入与肠道功能相关的病患报告结局。本引言为后续重点讨论治疗层级、剂型、区域市场驱动因素以及相关人员在寻求改善患者结局的同时，如何确保阿片类药物的充足供应等战略考虑奠定了基础。

快速发展的临床实践、支付方参与、数位监测和製剂创新正在推动阿片类药物引起的便秘管理进入一个新时代。

在临床、监管和患者体验等多方面因素的驱动下，阿片类药物引起的便秘（OIC）管理格局正在经历多项变革。首先，临床治疗正朝着标靶机制的治疗方法旨在解决受体介导的便秘问题，同时又不影响中枢镇痛效果。这种转变正在改变处方模式，并促使临床医生在治疗早期考虑使用周边作用的μ-阿片受体拮抗剂。其次，患者的期望和数位化医疗的普及正在重塑便秘的报告、监测和管理方式。行动症状追踪和远端医疗追踪正日益融入治疗方案中，从而能够更快地调整治疗方案。

第三，随着医疗系统寻求量化阿片类药物治疗对患者再入院率、住院时长和阿片类药物依从性等后续影响，支付方的参与度日益提高。因此，处方和用药管理也在不断发展，以反映临床效用和真实世界疗效的证据。第四，剂型和联合治疗的创新正在扩大临床医师的治疗选择。最后，疼痛专家、胃肠病学家和初级保健医生之间的多学科合作日益普遍，从而支持从阿片类药物治疗开始，贯穿常规随访和适应症扩展的综合路径。这些转变共同创造了一个环境，​​在这个环境中，临床疗效、以病人为中心的结果和经济因素相互交织，共同指南未来的投资和实践模式。

2025年关税改革如何重塑药品采购、供应链韧性与筹资策略，进而影响OIC疗法的可近性与成本动态

2025年关税政策和跨境贸易考量给阿片类药物诱导性胆汁淤积症（OIC）治疗相关的药品原料和成品的供应链带来了巨大压力。面对不断上涨的进口成本，生产商透过优化供应链、在地采购策略和战术性库存调整等方式来应对，以降低价格波动并维持供应的连续性。这些因应措施也促使业界更加关注区域性製造地，以减轻关税引发的成本波动影响，并建构更具韧性的经销网络。

同时，医院和经销商的采购团队正在调整合约策略，优先考虑多供应商和长期协议，以减轻短期关税波动的影响。临床相关人员注意到某些品牌学名药（尤其是特殊製剂）的供应受到间歇性影响，因此在临床适用的情况下，需要使用替代药物和给药途径。政策主导的成本压力促使人们重新关注成本效益评估、基于价值的协议谈判以及对供应链透明度的更严格审查。总而言之，2025年的关税环境凸显了在整个OIC治疗生态系统中采取灵活的筹资策略、积极主动的相关人员沟通以及製定综合应急计画的必要性。

细分的治疗和製剂概况揭示了联合治疗、泻药类别、受体拮抗剂和给药途径的临床、耐受性和商业性动态

透过详细的市场细分方法，可以揭示治疗层级和剂型之间的关键临床和商业差异，从而有助于制定标靶策略。按产品类型划分，市场包括：联合治疗（多种药物混合使用，可协同控制肠道功能）；传统泻药（又细分为渗透性泻药、刺激性泻药和具有不同作用机制的粪便软化剂）；以及外周作用的μ-阿片受体拮抗剂，包括阿维莫潘、甲基纳曲酮、纳美地林和纳洛昔醇等分子类型，这些特征和临床动力学​​特征具有不同的药物和临床动力学​​。这些产品层面的差异对临床路径、製剂偏好和实际耐受性具有重要意义。

在考虑口服给药途径时，製剂可分为液体和固态两种形式。液体製剂包括溶液和混悬剂，便于剂量调整，并能帮助儿童和吞嚥困难的患者；固态製剂包括胶囊和片剂，因其便利性和依从性，在门诊环境中更受欢迎。直肠给药，如灌肠剂或塞剂，可在急诊和安宁疗护中快速起效，发挥着虽小但重要的作用。跨领域因素，包括病患的人口统计特征、共病、特定给药途径的起效时间和製剂耐受性，指南临床医师的选择和支付方的定价。了解这些多层次细分市场的动态变化，有助于制定更精准的临床指南、处方策略和商业计划，使产品属性与患者的实际需求相符。

医疗保健系统、报销重点和处方习惯方面的区域差异将影响全球市场的接受度、取得策略和临床应用模式。

区域动态对阿片类药物引起的便秘的治疗可近性、临床医生行为和政策应对措施有显着影响，美洲、中东和非洲以及亚太地区的情况各有不同。在美洲，综合医疗体系和大型私人支付方市场重视临床疗效和病患报告指标，推动了标靶药物疗法的早期应用，并支持对依从性项目和数位监测的投资。该地区的监管路径也会影响适应症，进而影响临床应用和报销的讨论。

区域差异正在影响欧洲、中东和非洲的医疗实践模式。一些国家医疗体系优先考虑成本控制和集中采购，而另一些则强调与临床指南和专科转诊途径保持一致。这些差异导致先进药物和传统泻药的使用模式各不相同。在亚太地区，医疗基础设施的快速发展、专科医疗服务覆盖范围的扩大以及法律规范的不断完善，为标靶治疗的推广应用创造了新的机会，而成本敏感性和药物製剂供应的差异则影响着各地区的处方策略。在所有地区，人口趋势、阿片类药物处方规范和医疗体系优先事项相互作用，共同决定治疗方法的定位以及相关人员如何实施教育和推广计划。

随着传统製药公司、专科创新药厂、学名药和数位医疗合作伙伴寻求差异化的市场准入和实证策略，它们之间逐渐形成竞争动态。

阿片类药物诱导性胆管炎（OIC）治疗领域的竞争格局由成熟的製药创新企业、专业生物技术公司和非专利药生产商共同塑造，它们各自为治疗方法的选择和市场发展做出贡献。大型製药企业凭藉其规模优势、广泛的分销网络以及与支付方和医疗服务提供者建立的稳固关係，能够快速实现新药的商业化，并支持大量上市后证据的积累。专业生物技术公司通常采用以新型分子和机制为导向的创新方法，这种方法具有变革治疗模式的潜力，尤其是在强大的临床差异化和标靶标记的支持下。

学名药生产商和契约製造生产商正在推动价格竞争，并提高药品可及性，尤其是在成本是主要障碍的地区和医疗环境中。除了传统竞争对手之外，数位疗法和远端监测供应商等非製药企业也在影响病人参与和真实世界疗效评估，从而创造了伙伴关係机会。这些相关人员的成功越来越取决于他们建立真实世界证据、展现以病人为中心的益处以及应对复杂的支付方环境以获得有利的报销和纳入医保目录的能力。

为相关人员提供切实可行的策略建议，以加强证据产生、病患可及性、製剂多样性、供应弹性以及合作商业化方法。

为了改善阿片类药物引起的便秘（OIC）管理的患者疗效和商业性表现，行业、临床和支付方领导者应采取协同行动。首先，应优先产生和传播真实世界证据，将症状控制与疼痛治疗方案依从性和医疗资源利用率降低等有意义的疗效联繫​​起来。其次，应投资于以患者为中心的製剂和给药模式，以满足特定需求，例如为弱势群体提供液体製剂，为急诊环境提供直肠製剂，同时考虑联合治疗以简化治疗流程。

第三，我们将加强跨相关人员的教育倡议，利用数位化工具进行症状追踪和远端随访，以协调处方医生的知识、护理实践和患者自我管理。第四，我们将透过多元化采购来源、建立区域製造伙伴关係关係以及协商灵活的采购合约来增强供应链韧性，从而减轻政策干扰的影响。最后，我们将探索创新药厂、学名药公司和数位医疗公司之间的策略联盟，以在提高治疗效果的同时，改善病人参与。这些综合措施将有助于将鸦片类药物引起的便秘（OIC）管理有效整合到整体疼痛治疗方案中，从而增强我们的商业性地位。

采用透明的多来源研究途径，整合临床证据、监管影响、专家咨询和供应链分析，以提供有意义的见解和可行的建议。

本调查方法采用多源方法，结合同侪审查的临床文献、监管文件、专家临床访谈、支付方政策分析以及主要相关人员咨询，旨在对阿片类药物引起的便秘（OIC）管理形成平衡且实用的观点。研究优先考虑临床文献和指南审查，以确定治疗层级的标准治疗方案和作用机制；同时，监管文件为附加檔、适应症和安全性资讯提供了背景。对疼痛专家、胃肠病学家、处方集管理人员和药剂师的专家访谈，则为分析提供了真实世界的实践模式、耐受性考量和采购动态等方面的资讯。

为了补充定性研究结果，我们对产品系列、製剂供应和供应链安排进行了结构化审查，以获取商业和营运方面的观察资料。调查方法强调资讯来源交叉验证，以检验研究结果并识别共同的主题，确保研究洞察既反映临床实际情况，也兼顾营运限制。在整个研究过程中，我们始终避免依赖任何单一资讯来源，并透明地记录各项假设和局限性，以便读者能够基于适当的证据来解读我们的研究结果。

结论性观点，整合临床要务、证据优先事项和策略行动，以减轻病人负担，同时维持适当的鸦片类药物使用。

阿片类药物引起的便秘 (OIC) 问题处于临床需求、患者体验和商业性机会的交汇点。标靶药物药理学、不断变化的支付方期望以及数位化患者互动工具的融合，为相关人员提供了一个有利的环境，使他们能够将 OIC 管理重新定义为负责任的鸦片类药物治疗的重要组成部分。临床医生在积极预防和早期升级治疗策略方面具有优势，而製造商和支付方必须携手合作，协调各种患者需求的获取途径和价值论证。

展望未来，能够将可靠的临床证据、灵活的给药模式和以患者为中心的剂型整合到连贯的商业和临床策略中的公司，最有可能取得成功。透过优先考虑真实世界的结果、製剂的多样性以及系统层面的协作，相关人员既可以确保患者获得必要的阿片类镇痛药，又能减轻阿片类药物引起的便秘（OIC）对患者和医疗保健系统带来的负担。这一结论强调了在临床、商业和政策领域开展协调行动的必要性，以改善医疗品质和患者的生活品质。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 住院患者慢性癌痛管理中周边μ-阿片受体拮抗剂的使用增加
  • 在门诊环境中推广针对鸦片类药物引起的便秘的新型口服小分子疗法
  • 将数位治疗方法与行动医疗应用程式结合，用于即时监测阿片类药物引起的便秘严重程度。
  • 增加对含有缓解便秘机制的缓释性鸦片类药物组合药物的投资
  • 近期FDA扩大纳洛昔醇和纳多美明标籤适应症对鸦片类药物引起的便秘治疗流程的影响
  • Linaclotide和Plecanatide在仿单标示外治疗鸦片类药物引起的便秘（除大肠激躁症外）方面的市场渗透率
  • 采用以患者为中心的报销模式，以改善患者获得昂贵的阿片类药物引起的便秘治疗的机会。
  • 临床指引倡导对安宁疗护人群中的鸦片类药物引起的便秘早期疗育，其影响
  • 远端医疗咨询在优化农村医疗机构阿片类药物引起的便秘管理策略中的作用
  • 非处方阿片类药物引起的便秘药物的出现及其对处方药市场动态的影响

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 阿片类药物引起的便秘市场（依产品类型划分）

  • 联合治疗
  • 泻药
    • 渗透性泻药
    • 刺激性泻药
    • 软便剂
  • 週边作用的μ-阿片受体拮抗剂
    • 阿维莫潘
    • 甲基纳曲酮
    • 纳美地林
    • 纳罗基斯目标

9. 口服药物引起的鸦片类药物便秘市场

  • 液体
    • 液体
    • 暂停
  • 固态的
    • 胶囊
    • 药片

10. 阿片类药物引起的便秘市场－直肠给药

  • 灌肠
  • 栓剂

11. 阿片类药物引起的便秘市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

12. 阿片类药物引起的便秘市场（依组别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各国阿片类药物引起的便秘市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AstraZeneca plc
    • Shionogi & Co., Ltd.
    • H. Lundbeck A/S
    • Bausch Health Companies Inc.
    • Mundipharma International Limited
    • Merck & Co., Inc.
    • Valinor Pharma, LLC
Product Code: MRR-742BD5182A30

The Opioid Induced Constipation Market is projected to grow by USD 119.94 million at a CAGR of 6.94% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 70.10 million
Estimated Year [2025] USD 75.03 million
Forecast Year [2032] USD 119.94 million
CAGR (%) 6.94%

Contextualizing opioid induced constipation as an urgent clinical quality and patient experience priority that demands integrated care pathways and product innovation

Opioid induced constipation (OIC) represents a persistent and complex complication of opioid therapy that affects patient adherence, quality of life, and clinical outcomes. As opioid prescribing remains an essential component of pain management across acute and chronic care settings, OIC emerges as a predictable adverse effect that requires proactive assessment and integrated management strategies. Clinicians, payers, and product developers must reconcile the dual imperatives of effective analgesia and maintaining gastrointestinal function, prompting new clinical pathways and innovation in supportive therapies.

Contemporary practice increasingly emphasizes early risk identification, tailored prophylactic regimens, and a stepped approach to intervention that begins with lifestyle counseling and laxative selection and escalates to targeted agents when necessary. Alongside clinical practices, payers and health systems are re-evaluating formulary placement, reimbursement policies, and value frameworks to incorporate patient-reported outcomes related to bowel function. This introduction sets the stage for a focused examination of therapeutic classes, administration formats, regional market drivers, and strategic considerations for stakeholders seeking to improve patient outcomes while preserving appropriate opioid access.

Rapid evolution in clinical practice, payer engagement, digital monitoring, and formulation innovation catalyzing a new era in management of opioid induced constipation

The landscape of OIC management is undergoing several transformative shifts driven by clinical, regulatory, and patient-experience imperatives. First, there is a marked clinical pivot toward mechanism-targeted therapies that address receptor-mediated constipation without compromising central analgesia. This shift has altered prescribing patterns and prompted clinicians to consider peripherally acting mu-opioid receptor antagonists earlier in the treatment continuum. Second, patient expectations and digital health engagement are reshaping how constipation is reported, monitored, and managed; mobile symptom tracking and telemedicine follow-up are increasingly integrated into care plans, enabling more responsive therapy adjustments.

Third, payer engagement is intensifying as health systems seek to quantify the downstream effects of OIC on hospital readmissions, length of stay, and adherence to opioid regimens. Consequently, formularies and utilization management are evolving to reflect evidence around clinical benefit and real-world effectiveness. Fourth, innovation in dosage forms and combination therapies is expanding therapeutic choices for clinicians. Finally, interdisciplinary collaboration between pain specialists, gastroenterologists, and primary care providers is becoming more common, supporting comprehensive pathways that begin at opioid initiation and continue through routine follow-up and escalation where indicated. Together, these shifts create an environment in which clinical efficacy, patient-centered outcomes, and economic considerations intersect to guide future investment and practice patterns.

How 2025 tariff changes reshaped pharmaceutical sourcing, supply chain resilience, and procurement strategies affecting availability and cost dynamics of OIC therapies

Tariff policies and cross-border trade considerations introduced in 2025 have exerted measurable pressure on supply chains for pharmaceutical ingredients and finished dosage forms relevant to OIC therapies. Manufacturers faced with increased import costs have responded through supply chain rationalization, localized sourcing strategies, and tactical inventory adjustments to mitigate pricing volatility and maintain continuity of supply. These responses have also accelerated industry interest in regional manufacturing hubs to reduce exposure to tariff-driven cost swings and to support more resilient distribution networks.

In parallel, procurement teams at hospitals and distributors have adapted contracting strategies to prioritize multi-source suppliers and longer-term agreements that buffer short-term tariff fluctuations. Clinical stakeholders have observed intermittent impact on availability of specific branded and generic products, particularly in specialized formulations, prompting substitutions to alternative agents or administration routes where clinically appropriate. Policy-driven cost pressures have encouraged a renewed focus on cost-effectiveness assessments, negotiation of value-based agreements, and increased scrutiny of supply chain transparency. Collectively, the tariff environment of 2025 has reinforced the need for flexible sourcing strategies, proactive stakeholder communication, and integrated contingency planning across the OIC therapeutic ecosystem.

Segmented therapeutic and formulation profiles uncover distinct clinical, tolerability, and commercial dynamics across combination therapies, laxative classes, receptor antagonists, and administration routes

A detailed segmentation approach reveals important clinical and commercial differentials across therapeutic classes and administration formats that inform targeted strategies. When viewed through the lens of product type, the market comprises combination therapies that blend agents for synergistic bowel regulation, traditional laxatives subdivided into osmotic agents, stimulant options, and stool softeners that address different mechanisms of action, and peripherally acting mu-opioid receptor antagonists which include alvimopan, methylnaltrexone, naldemedine, and naloxegol as distinct molecular options with differing pharmacokinetic profiles and clinical indications. These product-level distinctions have practical implications for clinical pathways, prescribing preference, and real-world tolerability.

When considering oral administration channels, formulations segregate into liquid and solid formats; liquid presentations include solutions and suspensions that can support titration and pediatric or dysphagic populations, while solid formats encompass capsules and tablets favored for convenience and adherence in ambulatory care. Rectal interventions retain a niche yet critical role, delivered as enemas and suppositories that offer rapid effect in acute care and palliative contexts. Cross-segment considerations such as patient demographics, comorbidities, route-specific onset of action, and formulation tolerability guide clinician choice and payer positioning. Understanding these layered segmentation dynamics enables more precise clinical guideline development, formulary strategies, and commercial planning that align product characteristics to real-world patient needs.

Regional differences in healthcare systems, reimbursement priorities, and prescribing norms that determine uptake, access strategies, and clinical adoption patterns across global markets

Regional dynamics exert substantial influence on access, clinician behavior, and policy responses to opioid induced constipation, with distinct drivers in the Americas, Europe Middle East & Africa, and Asia-Pacific regions. In the Americas, integrated health systems and large private payer markets emphasize clinical outcomes and patient-reported measures, driving early adoption of targeted pharmacotherapies and supporting investments in adherence programs and digital monitoring. Regulatory pathways in this region also influence label indications, which in turn affect clinical utilization and reimbursement discussions.

In Europe, Middle East & Africa, regional heterogeneity shapes practice patterns; some national systems prioritize cost-containment and centralized procurement while others emphasize clinical guideline alignment and specialist referral pathways. These differences create varied uptake patterns for advanced agents versus traditional laxatives. In the Asia-Pacific region, rapid growth in healthcare infrastructure, expanding access to specialist care, and evolving regulatory frameworks are creating new opportunities for adoption of targeted therapies, while cost-sensitivity and variable availability of formulations inform local prescribing strategies. Across all regions, demographic trends, opioid prescribing norms, and health system priorities interact to determine how therapies are positioned and how stakeholder education and access initiatives are implemented.

Competitive dynamics shaped by established pharmaceutical players, specialty innovators, generics, and digital health collaborators driving differentiated access and evidence strategies

The competitive landscape for OIC therapies is shaped by established pharmaceutical innovators, specialty biotech entrants, and generic manufacturers, each contributing to therapeutic choice and market evolution. Large manufacturers bring scale, broad distribution networks, and established relationships with payers and providers, enabling rapid commercialization of new agents and supporting extensive post-marketing evidence generation. Specialty biotech firms often drive innovation with novel molecules and mechanism-focused approaches that can shift treatment paradigms, particularly when supported by strong clinical differentiation and targeted labeling.

Generic manufacturers and contract producers contribute to price competition and accessibility, particularly in regions and care settings where cost is a primary barrier. In addition to traditional competitors, non-pharmaceutical players such as digital therapeutics and remote monitoring vendors are influencing patient engagement and real-world outcome measurement, creating opportunities for partnership. Across these actors, success is increasingly determined by the ability to generate real-world evidence, demonstrate patient-centered benefits, and navigate complex payer environments to secure favorable reimbursement and formulary placement.

Practical and strategic recommendations for stakeholders to strengthen evidence generation, patient access, formulation diversity, supply resilience, and collaborative commercialization approaches

Leaders across industry, clinical practice, and payer organizations should take coordinated actions to improve patient outcomes and commercial performance in OIC management. First, prioritize generation and dissemination of real-world evidence that links symptom control to meaningful outcomes such as adherence to analgesic regimens and reduction in healthcare utilization; such evidence strengthens value dialogues with payers and prescribers. Second, invest in patient-centric formulation development and access models that address specific needs, including liquid options for vulnerable populations and rectal formulations for acute care settings, while considering opportunities for combination therapies that streamline care.

Third, enhance cross-stakeholder education initiatives that align prescriber knowledge, nursing practice, and patient self-management, leveraging digital tools for symptom tracking and remote follow-up. Fourth, reinforce supply chain resilience by diversifying sourcing, establishing regional manufacturing partnerships, and negotiating flexible procurement contracts to mitigate policy-driven disruptions. Finally, explore strategic collaborations between innovators, generics, and digital health firms to combine therapeutic efficacy with improved adherence and patient engagement. These actions, taken together, will enable more effective integration of OIC management into holistic pain care pathways and strengthen commercial positioning.

A transparent multi-source research approach integrating clinical evidence, regulatory review, expert consultation, and supply chain analysis to produce validated insights and practical implications

This research synthesizes a multi-source methodology combining peer-reviewed clinical literature, regulatory documentation, expert clinician interviews, payer policy analysis, and primary stakeholder consultations to construct a balanced and actionable perspective on OIC management. Clinical literature and guideline reviews were prioritized to establish accepted standards of care and mechanistic rationale for therapeutic classes, while regulatory documents provided context on labeling, indications, and safety communications. Expert interviews with pain specialists, gastroenterologists, formulary managers, and pharmacists enriched the analysis with real-world practice patterns, tolerability considerations, and procurement dynamics.

Complementing qualitative inputs, a structured review of product portfolios, formulation availability, and supply chain arrangements informed commercial and operational observations. The methodology emphasized triangulation across sources to validate findings and identify convergent themes, ensuring that insights reflect both clinical realities and operational constraints. Throughout the research process, care was taken to avoid reliance on single-source data and to document assumptions and limitations transparently, enabling readers to interpret findings within the appropriate evidentiary context.

Concluding perspective that integrates clinical imperatives, evidence priorities, and strategic actions to reduce patient burden while preserving appropriate opioid access

Opioid induced constipation stands at the intersection of clinical need, patient experience, and commercial opportunity. The convergence of targeted pharmacology, evolving payer expectations, and digital patient engagement tools presents a compelling environment for stakeholders to reframe OIC management as an integral component of responsible opioid therapy. Clinicians are positioned to incorporate proactive prevention and earlier escalation strategies, while manufacturers and payers must collaborate to align value demonstration with access pathways that meet diverse patient needs.

Looking ahead, success will favor actors who can integrate robust clinical evidence, adaptable supply models, and patient-centric delivery formats into coherent commercial and clinical strategies. By prioritizing real-world outcomes, formulation diversity, and system-level collaboration, stakeholders can reduce the burden of OIC on patients and health systems while preserving necessary access to opioid analgesia. This conclusion underscores the imperative for coordinated action across clinical, commercial, and policy domains to improve both quality of care and patient quality of life.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising uptake of peripherally acting mu-opioid receptor antagonists in hospitalized patients with chronic cancer pain management
  • 5.2. Expansion of novel oral small molecule treatments targeting opioid-induced constipation symptoms in outpatient settings
  • 5.3. Integration of digital therapeutics and mobile health apps for real-time monitoring of opioid-induced constipation severity
  • 5.4. Increasing investment in extended-release combination opioid formulations with built-in constipation mitigation mechanisms
  • 5.5. Impact of recent FDA label expansions for naloxegol and naldemedine on opioid-induced constipation treatment algorithms
  • 5.6. Market penetration of linaclotide and plecanatide beyond irritable bowel syndrome for opioid-induced constipation off-label use
  • 5.7. Adoption of patient-centric reimbursement models to improve access to expensive opioid-induced constipation therapies
  • 5.8. Influence of clinical guidelines advocating early intervention for opioid-induced constipation among palliative care populations
  • 5.9. Role of telemedicine consultations in optimizing management strategies for opioid-induced constipation in rural healthcare settings
  • 5.10. Emergence of over-the-counter opioid-induced constipation remedies and their effect on prescription market dynamics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Opioid Induced Constipation Market, by Product Type

  • 8.1. Combination Therapies
  • 8.2. Laxatives
    • 8.2.1. Osmotic Laxatives
    • 8.2.2. Stimulant Laxatives
    • 8.2.3. Stool Softeners
  • 8.3. Peripherally Acting Mu-Opioid Receptor Antagonists
    • 8.3.1. Alvimopan
    • 8.3.2. Methylnaltrexone
    • 8.3.3. Naldemedine
    • 8.3.4. Naloxegol

9. Opioid Induced Constipation Market, by Oral

  • 9.1. Liquid
    • 9.1.1. Solutions
    • 9.1.2. Suspensions
  • 9.2. Solid
    • 9.2.1. Capsules
    • 9.2.2. Tablets

10. Opioid Induced Constipation Market, by Rectal

  • 10.1. Enemas
  • 10.2. Suppositories

11. Opioid Induced Constipation Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Opioid Induced Constipation Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Opioid Induced Constipation Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. AstraZeneca plc
    • 14.3.2. Shionogi & Co., Ltd.
    • 14.3.3. H. Lundbeck A/S
    • 14.3.4. Bausch Health Companies Inc.
    • 14.3.5. Mundipharma International Limited
    • 14.3.6. Merck & Co., Inc.
    • 14.3.7. Valinor Pharma, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OPIOID INDUCED CONSTIPATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 275. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 280. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 281. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 282. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 283. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 284. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 285. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 286. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 287. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 288. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 289. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 290. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS OPIOID INDUCED CONS